<DOC>
	<DOCNO>NCT03089775</DOCNO>
	<brief_summary>This two cohort study ( Cohort A B ) conduct assess safety efficacy BBI-2000 prevention ( Cohort A ) treatment ( Cohort B ) delay type hypersensitivity reaction .</brief_summary>
	<brief_title>Evaluation Safety Efficacy BBI-2000 Treating Preventing Contact Dermatitis</brief_title>
	<detailed_description>This two cohort ( Cohort A B ) single-center , randomize , control study conduct evaluate safety efficacy BBI-2000 prevention ( Cohort A ) treatment ( Cohort B ) delay type hypersensitivity ( DTH ) reaction . Subjects Cohort A initially receive either pre-treatment BBI-2000 vehicle , area back . Diphencyprone ( DPCP ) administer , via Finn chamber , area back . The treated area assess determine BBI-2000 effective preventing contact hypersensitivity reaction . Cohort B first sensitize DPCP Cohort A . Indicated region back challenge illicit DTH reaction . Following challenge , indicate region subject 's back treat either ( A ) BBI-2000 , ( B ) vehicle , ( C ) topical application ( D ) clobetasol propionate . The efficacy BBI-2000 evaluate monitor response area contact hypersensitivity reaction .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Contact</mesh_term>
	<criteria>Individuals age 18 65 year inclusive time consent , either female nonreproductive potential male . Subjects must healthy , normal volunteer per physical exam , laboratory EKG assessments History contact dermatitis medical adhesive bandage glue . Medical history dermatographism . Any medical condition cause immunosuppression . Prior treatment therapy history sensitivity study product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Contact</keyword>
	<keyword>Treatment</keyword>
	<keyword>Prevention</keyword>
	<keyword>BBI-2000</keyword>
	<keyword>Dermatitis</keyword>
	<keyword>Allergic</keyword>
</DOC>